title: [Treatment and prevention of infections in cancer patients with neutropenia].
abstract: Prognosis of malignant diseases is significantly influenced by infectious morbidity and mortality. Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections. In order to improve outcome, patients developing febrile neutropenia following antitumour treatment should be adequately informed regarding the risk of infections. At the same time, centres responsible for cancer patient care should set up written protocols for basic workup and empirical antibiotic therapy. Here general characteristics of neutropenic infections developing in solid tumour patients are outlined and key points for risk assessment are highlighted. In addition, options and limits of anti-infective therapy as well as prophylaxis of infections are reviewed. Importance of a fully functional institutional infection control system and multidisciplinary patient management is also emphasised.
authors.affiliation: Fõvárosi Önkormányzat Egyesített Szent István és Szent László Kórház - Rendelõintézet, Budapest, Hungary. janos.sinko@gmail.com
authors.forename: János
authors.initials: J
authors.lastname: Sinkó
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002939:Ciprofloxacin / Q000008:administration & dosage; D002985:Clinical Protocols; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005334:Fever / Q000382:microbiology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications* / Q000517:prevention & control; D015242:Ofloxacin / Q000008:administration & dosage; D010348:Patient Care Team; D018570:Risk Assessment
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D002939:Ciprofloxacin; D015242:Ofloxacin